Cargando…
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
IMPORTANCE: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To compare precision medicine data and outcomes between Black and White men with...
Autores principales: | Hwang, Clara, Henderson, Nicholas C., Chu, Shih-Chun, Holland, Brandon, Cackowski, Frank C., Pilling, Amanda, Jang, Albert, Rothstein, Shoshana, Labriola, Matthew, Park, Joseph J., Ghose, Alyssa, Bilen, Mehmet A., Mustafa, Seema, Kilari, Deepak, Pierro, Michael J., Thapa, Bicky, Tripathi, Abhishek, Garje, Rohan, Ravindra, Aditya, Koshkin, Vadim S., Hernandez, Erik, Schweizer, Michael T., Armstrong, Andrew J., McKay, Rana R., Dorff, Tanya B., Alva, Ajjai S., Barata, Pedro C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507489/ https://www.ncbi.nlm.nih.gov/pubmed/37721753 http://dx.doi.org/10.1001/jamanetworkopen.2023.34208 |
Ejemplares similares
-
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration
por: Dorff, Tanya, et al.
Publicado: (2023) -
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
por: Koshkin, Vadim S., et al.
Publicado: (2021) -
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018) -
Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019) -
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)